Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraovarian PRGF in Low Ovarian Reserve
NCT06975683Phase 2Recruiting
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PRGF-Endoret in Diminished Ovarian Reserve (DOR), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoints: Number of cycles cancelled pre-puncture at Day 1, Ovarian reserve markers at 4 weeks and 7 more. Started May 2025; status: recruiting.
02
Drugs
PRGF-Endoret
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT06975683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975683.